Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study
Background: Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). Methods: This was a single-center, retrospective, observat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-03-01
|
| Series: | Cephalalgia Reports |
| Online Access: | https://doi.org/10.1177/25158163241238448 |
| _version_ | 1797234643071664128 |
|---|---|
| author | Hsiangkuo Yuan Fred Cohen Maurice T Driessen Lynda J Krasenbaum Mario Ortega Mary Hopkins Michael J Marmura |
| author_facet | Hsiangkuo Yuan Fred Cohen Maurice T Driessen Lynda J Krasenbaum Mario Ortega Mary Hopkins Michael J Marmura |
| author_sort | Hsiangkuo Yuan |
| collection | DOAJ |
| description | Background: Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). Methods: This was a single-center, retrospective, observational study that assessed treatment response (change over time in monthly headache days [MHD] and pain intensity [PI]) in adult patients with CM receiving fremanezumab as add-on therapy to onabotA for CM prevention. Results: In the study population ( N = 116, age 50.0 ± 13.1, female 85.3%, pre-index onabotA use 46.5 ± 34.2 months) receiving concurrent onabotA and fremanezumab for 17.5 ± 11.6 months, MHD decreased by 3.60 days (95% confidence interval [CI]: −5.26, −1.94, p < 0.001) and PI was reduced by 0.43 (95% CI: −0.77, −0.09, p = 0.012) at the final visit. Statistically significant reductions were seen in both MHD (−4.61, 95% CI: −6.84, −2.39; p < 0.001) and PI (−0.52, 95% CI: −0.84. −0.09; p = 0.017) among patients naïve to mAbs against CGRP or its receptor. No unexpected adverse events were observed. Conclusion: Concomitant fremanezumab and onabotA for CM prevention were effective at reducing the number of MHD and lessening PI, particularly in patients with difficult-to-treat CM who are naïve to mAbs against CGRP or its receptor. |
| first_indexed | 2024-04-24T16:35:19Z |
| format | Article |
| id | doaj.art-bc79059de0f142e58d6ef24009062785 |
| institution | Directory Open Access Journal |
| issn | 2515-8163 |
| language | English |
| last_indexed | 2024-04-24T16:35:19Z |
| publishDate | 2024-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cephalalgia Reports |
| spelling | doaj.art-bc79059de0f142e58d6ef240090627852024-03-29T17:03:29ZengSAGE PublishingCephalalgia Reports2515-81632024-03-01710.1177/25158163241238448Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review studyHsiangkuo Yuan0Fred Cohen1Maurice T Driessen2Lynda J Krasenbaum3Mario Ortega4Mary Hopkins5Michael J Marmura6 Department of Neurology, Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA Department of Neurology, Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA Teva Pharmaceuticals, Amsterdam, The Netherlands Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA Teva Pharmaceuticals, Parsippany, NJ, USA Department of Neurology, Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA Department of Neurology, Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USABackground: Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). Methods: This was a single-center, retrospective, observational study that assessed treatment response (change over time in monthly headache days [MHD] and pain intensity [PI]) in adult patients with CM receiving fremanezumab as add-on therapy to onabotA for CM prevention. Results: In the study population ( N = 116, age 50.0 ± 13.1, female 85.3%, pre-index onabotA use 46.5 ± 34.2 months) receiving concurrent onabotA and fremanezumab for 17.5 ± 11.6 months, MHD decreased by 3.60 days (95% confidence interval [CI]: −5.26, −1.94, p < 0.001) and PI was reduced by 0.43 (95% CI: −0.77, −0.09, p = 0.012) at the final visit. Statistically significant reductions were seen in both MHD (−4.61, 95% CI: −6.84, −2.39; p < 0.001) and PI (−0.52, 95% CI: −0.84. −0.09; p = 0.017) among patients naïve to mAbs against CGRP or its receptor. No unexpected adverse events were observed. Conclusion: Concomitant fremanezumab and onabotA for CM prevention were effective at reducing the number of MHD and lessening PI, particularly in patients with difficult-to-treat CM who are naïve to mAbs against CGRP or its receptor.https://doi.org/10.1177/25158163241238448 |
| spellingShingle | Hsiangkuo Yuan Fred Cohen Maurice T Driessen Lynda J Krasenbaum Mario Ortega Mary Hopkins Michael J Marmura Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study Cephalalgia Reports |
| title | Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study |
| title_full | Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study |
| title_fullStr | Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study |
| title_full_unstemmed | Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study |
| title_short | Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study |
| title_sort | real world effectiveness of add on fremanezumab in patients receiving onabotulinumtoxina for the prevention of chronic migraine in a us tertiary headache center a retrospective chart review study |
| url | https://doi.org/10.1177/25158163241238448 |
| work_keys_str_mv | AT hsiangkuoyuan realworldeffectivenessofaddonfremanezumabinpatientsreceivingonabotulinumtoxinaforthepreventionofchronicmigraineinaustertiaryheadachecenteraretrospectivechartreviewstudy AT fredcohen realworldeffectivenessofaddonfremanezumabinpatientsreceivingonabotulinumtoxinaforthepreventionofchronicmigraineinaustertiaryheadachecenteraretrospectivechartreviewstudy AT mauricetdriessen realworldeffectivenessofaddonfremanezumabinpatientsreceivingonabotulinumtoxinaforthepreventionofchronicmigraineinaustertiaryheadachecenteraretrospectivechartreviewstudy AT lyndajkrasenbaum realworldeffectivenessofaddonfremanezumabinpatientsreceivingonabotulinumtoxinaforthepreventionofchronicmigraineinaustertiaryheadachecenteraretrospectivechartreviewstudy AT marioortega realworldeffectivenessofaddonfremanezumabinpatientsreceivingonabotulinumtoxinaforthepreventionofchronicmigraineinaustertiaryheadachecenteraretrospectivechartreviewstudy AT maryhopkins realworldeffectivenessofaddonfremanezumabinpatientsreceivingonabotulinumtoxinaforthepreventionofchronicmigraineinaustertiaryheadachecenteraretrospectivechartreviewstudy AT michaeljmarmura realworldeffectivenessofaddonfremanezumabinpatientsreceivingonabotulinumtoxinaforthepreventionofchronicmigraineinaustertiaryheadachecenteraretrospectivechartreviewstudy |